{"result": "(\"entity\"<|>MNGIE<|>EVENT<|>Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder that affects the gastrointestinal and nervous systems, leading to various metabolic issues and requiring complex treatment approaches.)\n##\n(\"entity\"<|>TIMIDIN FOSFORILASA<|>ORGANIZATION<|>Thymidine phosphorylase is an enzyme whose activity is crucial for metabolic processes, particularly in patients with MNGIE.)\n##\n(\"entity\"<|>HEMATOPOLYETIC STEM CELL TRANSPLANT<|>EVENT<|>A treatment option for MNGIE that involves transplanting stem cells to restore enzyme activity, though it has a high mortality rate.)\n##\n(\"entity\"<|>ORTOTOPIC LIVER TRANSPLANT<|>EVENT<|>A surgical procedure that involves transplanting a liver into a patient, which can provide a source of thymidine phosphorylase for MNGIE patients.)\n##\n(\"entity\"<|>COENZYME Q10<|>ORGANIZATION<|>Coenzyme Q10 is a supplement used to support mitochondrial function and is part of the treatment regimen for patients with mitochondrial disorders.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>A metabolic disorder that affects how the body processes blood sugar, which is relevant in the context of the patient's treatment.)\n##\n(\"entity\"<|>PATIENT<|>PERSON<|>The individual undergoing treatment for MNGIE, experiencing various symptoms and requiring a multidisciplinary approach for management.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPLEMENTS<|>ORGANIZATION<|>Specific dietary supplements prescribed to the patient to stabilize weight and manage symptoms related to MNGIE and diabetes.)\n##\n(\"relationship\"<|>PATIENT<|>MNGIE<|>The patient is diagnosed with MNGIE, which dictates their treatment and management plan.<|>10)\n##\n(\"relationship\"<|>MNGIE<|>HEMATOPOLYETIC STEM CELL TRANSPLANT<|>Hematopoietic stem cell transplant is a treatment option considered for MNGIE patients, despite its high mortality risk.<|>7)\n##\n(\"relationship\"<|>MNGIE<|>ORTOTOPIC LIVER TRANSPLANT<|>Ortotopic liver transplant is a viable alternative treatment for MNGIE patients, providing a source of thymidine phosphorylase.<|>8)\n##\n(\"relationship\"<|>PATIENT<|>DIABETES<|>The patient has diabetes, which complicates their treatment for MNGIE and requires careful management of their medication.<|>9)\n##\n(\"relationship\"<|>PATIENT<|>NUTRITIONAL SUPPLEMENTS<|>Nutritional supplements are prescribed to the patient to help manage their weight and overall health in the context of MNGIE and diabetes.<|>8)\n##\n(\"relationship\"<|>TIMIDIN FOSFORILASA<|>ORTOTOPIC LIVER TRANSPLANT<|>Ortotopic liver transplant provides thymidine phosphorylase, which is essential for treating MNGIE.<|>9)\n##\n(\"relationship\"<|>COENZYME Q10<|>PATIENT<|>Coenzyme Q10 is part of the treatment regimen for the patient to support mitochondrial function.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: regir el déficit enzimático, con el propósito de corregir los daños metabólicos al restaurar la actividad de la timidin fosforilasa, disminuyendo las concentraciones plasmáticas de timidina y deoxiuridina. Más de diez pacientes con MNGIE han sido tratados con trasplante de células hematopoyéticas⁹. Sin embargo, este tratamiento presenta un alto porcentaje de mortalidad de hasta el 70%. El trasplante hepático ortotópico es una buena alternativa en los pacientes con MNGIE dado que el hígado es una fuente importante de timidin fosforilasa. Presenta menos riesgo de morbi-mortalidad que el trasplante de células hematopoyéticas, efecto duradero a diferencia de la diálisis y la infusión de plaquetas, y es una opción terapéutica a considerar en relación a la mejoría de la supervivencia en este tipo de pacientes¹⁰.\n---\nEl paciente que comentamos presentaba una situación de desnutrición calórica importante, junto con síntomas de dismotilidad intestinal con plenitud postprandial y diarrea. Recibió recomendaciones dietéticas y se pautaron suplementos nutricionales orales específicos de diabetes, que aportaban 900 kcal al día, consiguiendo estabilizar peso. Por otra parte, se inició tratamiento con antidiabéticos orales. Hay que tener en cuenta que, al presentar el paciente una diabetes mitocondrial, hay que evitar el tratamiento con metformina, dado el riesgo de acidosis láctica más acentuado en estos pacientes. Posteriormente, a pesar del tratamiento con dos antidiabéticos orales, sitagliptina 100 mg/día y repaglinida 1 mg cada 8 horas, persistían glucemias elevadas, fundamentalmente preprandiales por lo que se añadió insulina basal. En este sentido, se intentó simplificar lo máximo en el tratamiento insulínico, tanto por la imposibilidad de autoinyección del paciente secundaria a la amaurosis como por la dificultad en la comprensión del ajuste de dosis de insulina en función de glucemias por parte de la cuidadora principal (madre). Además, se pautó tratamiento con coenzima Q 10 400 mg/día, cápsulas de ácidos grasos omega 3 y L-carnitina 1 g al día.\n\nSe derivó a Hematología para valoración de la posibilidad de trasplante de células hematopoyéticas siendo desestimando el tratamiento. Posteriormente, se derivó a Cirugía para valoración del trasplante hepático si bien también fue desestimado. En esta situación sólo quedan medidas sintomáticas, ya que muchos pacientes progresan a pseudoobstrucciones intestinales que obligan a nutrirlos vía parenteral. De momento, el paciente que presentamos no ha llegado a esta situación.\n\n## Conclusiones\n\nEl síndrome de encefalopatía mitocondrial neurogastrointestinal con polineuropatía sensitivo-motora es una patología compleja que requiere un abordaje multidisciplinar. Las opciones terapéuticas son limitadas e incluyen soporte nutricional, suplementación de cofactores, así como trasplante de médula ósea y trasplante hepático en determinadas situaciones.\n---\n# Bibliografía\n\n1. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011;134:3326-32.\n\n2. Xieng Y, Gu WY, Hou XL, yang YL, Jiang Y, Zhou CL. Mitocondrial hyneurogastrointestinal encephalomyopathy of neonatal onset: a case report and literature review. Chin J Evid Based Pediatr. 2013;8:126-30.\n\n3. Martí R, Spinazzola A, Tadesse S. Definitive diagnosis of mitocondrial neurogastointestinal encephalomyopathy by biochemical assays. Clin Chem. 2004;50:1203124.\n\n4. Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012;4:CD004426.\n\n5. Chen RS, Huang CC, Chu NS, Coenzyme Q 10 treatment in ophthalmoplegia plus –a doble- blind crossover study. Eur neurol.1997;37:212.\n\n6. Tarnopolsky MA, Roy BD, Mc Donald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle nerv.1997; 20:1502.\n\n7. Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology. 2000;55:1748.\n\n8. Dimauro S, hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve. 2006; 34:265.\n\n9. Filosto M, Scarpelli M, Tonin P, et al. Course and management of allogeneic stem cell transplantation\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}